-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Imago BioSciences (NASDAQ:IMGO) Shares Gap Up to $14.88
Imago BioSciences (NASDAQ:IMGO) Shares Gap Up to $14.88
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $14.88, but opened at $15.30. Imago BioSciences shares last traded at $15.30, with a volume of 100 shares traded.
Analysts Set New Price Targets
Separately, HC Wainwright lowered their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
Get Imago BioSciences alerts:Imago BioSciences Stock Up 1.9 %
The business's 50 day moving average is $16.32 and its 200-day moving average is $17.09. The firm has a market capitalization of $565.85 million, a P/E ratio of -9.42 and a beta of 2.48.
Insider Activity at Imago BioSciences
In related news, insider Jennifer Peppe sold 5,598 shares of Imago BioSciences stock in a transaction that occurred on Monday, August 15th. The shares were sold at an average price of $19.41, for a total value of $108,657.18. Following the transaction, the insider now directly owns 148,809 shares of the company's stock, valued at $2,888,382.69. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 8,168 shares of company stock valued at $155,402 over the last three months. 14.90% of the stock is owned by insiders.Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in IMGO. Northern Trust Corp increased its stake in Imago BioSciences by 25.0% in the fourth quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after acquiring an additional 21,413 shares during the last quarter. Swiss National Bank acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $612,000. Ensign Peak Advisors Inc acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $593,000. Virtus ETF Advisers LLC acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $215,000. Finally, Citadel Advisors LLC boosted its position in Imago BioSciences by 20.1% in the fourth quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after buying an additional 410,487 shares in the last quarter. 99.50% of the stock is owned by institutional investors.
Imago BioSciences Company Profile
(Get Rating)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
Read More
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
Imago BioSciences, Inc. (NASDAQ:IMGO – Get Rating) shares gapped up before the market opened on Wednesday . The stock had previously closed at $14.88, but opened at $15.30. Imago BioSciences shares last traded at $15.30, with a volume of 100 shares traded.
意馬生物科學公司(納斯達克代碼：IMGO-GET Rating)的股票在週三開盤前大幅上漲。該股此前收盤報14.88美元，開盤報15.30美元。Imago BioSciences的股票尾盤報15.30美元，成交量為100股。
Analysts Set New Price Targets
分析師設定新的價格目標
Separately, HC Wainwright lowered their target price on shares of Imago BioSciences from $36.00 to $35.00 and set a "buy" rating on the stock in a report on Tuesday, August 16th.
另外，在8月16日(星期二)的一份報告中，HC Wainwright將Imago BioSciences的目標價從36.00美元下調至35.00美元，並對該股設定了買入評級。
Imago BioSciences Stock Up 1.9 %
Imago BioSciences股價上漲1.9%
The business's 50 day moving average is $16.32 and its 200-day moving average is $17.09. The firm has a market capitalization of $565.85 million, a P/E ratio of -9.42 and a beta of 2.48.
該業務的50日移動均線切入位在16.32美元，200日移動均線切入位在17.09美元。該公司的市值為5.6585億美元，市盈率為-9.42，貝塔係數為2.48。
Insider Activity at Imago BioSciences
Imago BioSciences的內部活動
Institutional Inflows and Outflows
機構資金流入和流出
A number of hedge funds have recently added to or reduced their stakes in IMGO. Northern Trust Corp increased its stake in Imago BioSciences by 25.0% in the fourth quarter. Northern Trust Corp now owns 107,122 shares of the company's stock valued at $2,541,000 after acquiring an additional 21,413 shares during the last quarter. Swiss National Bank acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $612,000. Ensign Peak Advisors Inc acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $593,000. Virtus ETF Advisers LLC acquired a new stake in Imago BioSciences in the fourth quarter valued at approximately $215,000. Finally, Citadel Advisors LLC boosted its position in Imago BioSciences by 20.1% in the fourth quarter. Citadel Advisors LLC now owns 2,452,926 shares of the company's stock valued at $57,271,000 after buying an additional 410,487 shares in the last quarter. 99.50% of the stock is owned by institutional investors.
一些對衝基金最近增持或減持了IMGO的股份。北方信託公司在第四季度增持了Imago BioSciences 25.0%的股份。Northern Trust Corp目前持有107,122股該公司股票，價值2,541,000美元，此前該公司在上一季度增持了21,413股。瑞士國家銀行在第四季度收購了Imago BioSciences的新股份，價值約為61.2萬美元。Ensign Peak Advisors Inc.在第四季度收購了Imago BioSciences的新股份，價值約593,000美元。Virtus ETF Advisers LLC在第四季度收購了Imago BioSciences的新股份，價值約21.5萬美元。最後，Citadel Advisors LLC在第四季度將其在Imago BioSciences的地位提高了20.1%。Citadel Advisors LLC現在擁有2,452,926股該公司股票，價值57,271,000美元，上個季度又購買了410,487股。99.50%的股票由機構投資者持有。
Imago BioSciences Company Profile
Imago BioSciences公司簡介
(Get Rating)
(獲取評級)
Imago BioSciences, Inc, a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera.
臨牀階段生物製藥公司Imago BioSciences，Inc.發現和開發了針對賴氨酸特異性脱甲基酶1(LSD1)的小分子產品候選產品，LSD1是一種用於生產骨髓中血細胞的酶。它的主要候選產品是Bomedemstat，正在進行第二階段臨牀試驗，用於治療骨髓增生性腫瘤和慢性骨髓癌，如骨髓纖維化、原發性血小板增多症和真性紅細胞增多症。
Read More
閲讀更多內容
- Get a free copy of the StockNews.com research report on Imago BioSciences (IMGO)
- Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
- Are These Green Energy Companies Right For Your Portfolio?
- When Will the Hangover Finally Be Over for Seagate Technology?
- Does Enphase Energy Have the Juice to Keep Powering Higher?
- The One Hydrogen Fuel Cell Stock To Rule Them All
- 免費獲取StockNews.com關於Imago BioSciences(IMGO)的研究報告
- 石油和天然氣股票：投資可再生能源的安全途徑
- 這些綠色能源公司適合你的投資組合嗎？
- 希捷科技的宿醉何時才能結束？
- 安相能源有足夠的動力繼續提高動力嗎？
- 獨一無二的氫燃料電池庫存
Receive News & Ratings for Imago BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imago BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受Imago生物科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Imago BioSciences和相關公司的最新新聞和分析師評級的每日簡要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧